Cargando…

The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

BACKGROUND: The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in 2nd-line non-small-cell lung cancer (NSCLC). 2- Compare costs and value of Niv...

Descripción completa

Detalles Bibliográficos
Autor principal:	Guirgis, Helmy M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819662/ https://www.ncbi.nlm.nih.gov/pubmed/29463302 http://dx.doi.org/10.1186/s40425-018-0320-3

Ejemplares similares

Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018)

Immune Check Point Inhibitor–Associated Endothelialitis
por: Bobart, Shane A., et al.
Publicado: (2020)

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)

PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study
por: Crescenzi, Anna, et al.
Publicado: (2017)

Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy
por: Vergne-Santiago, Norma, et al.
Publicado: (2021)

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors
por: Rosenberg, Mark A, et al.
Publicado: (2015)

Small bowel hemorrhage from check point inhibitor enteritis: a case report
por: Young, Kellie, et al.
Publicado: (2021)

Targeted therapy of ovarian cancer including immune check point inhibitor
por: Kim, Jin Young, et al.
Publicado: (2017)

SAT-239 Combination of Immune Check Point Inhibitors Causing Hypopituitarism
por: Dhillon, Puneet, et al.
Publicado: (2020)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report
por: Iwai, Shun, et al.
Publicado: (2020)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

FRI332 Check Point Inhibitor Induced Hypophysitis/Hypopituitarism
por: Chandpuri, Ranjit Singh
Publicado: (2023)

SAT-493 A Case of Profound Hypothyroidism Secondary to Immune Check Point Inhibitors
por: Tun, Yin Nwe, et al.
Publicado: (2020)

Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research
por: Varayathu, Hrishi, et al.
Publicado: (2021)

Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
por: De Felice, Francesca, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment
por: Wiegand, Susanne, et al.
Publicado: (2019)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review
por: Khaddour, Karam, et al.
Publicado: (2019)

Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
por: Garon-Czmil, Julie, et al.
Publicado: (2019)

Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review
por: Arcari, Luca, et al.
Publicado: (2022)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Novel Immune Check-Point Regulators in Tolerance Maintenance
por: Guo, Yanxia, et al.
Publicado: (2015)

First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function
por: Myers, Jamie S., et al.
Publicado: (2023)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Tracking Actomyosin at Fluorescence Check Points
por: Lard, Mercy, et al.
Publicado: (2013)

Erratum: Novel Immune Check-Point Regulators in Tolerance Maintenance
Publicado: (2016)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
por: Byeon, S., et al.
Publicado: (2020)

Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
por: Luangnara, Athitaya, et al.
Publicado: (2022)

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
por: Song, Peng, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
por: Poletajew, Sławomir, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ndoeu4h19s279p8ejrm0uogmqg